Everolimus trials for Metastatic Breast Cancer

All Everolimus trials · All Metastatic Breast Cancer trials

Phase breakdown

Recruiting trials studying Everolimus for Metastatic Breast Cancer

• Everolimus With Investigator's Choice of Chemotherapy in Advanced Triple-Negative Breast Cancer (TNBC) With Luminal Androgen Receptor (LAR) Subtype
  NCT05954442 · Phase: Phase 3 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
  NCT05573126 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: Female · 14 locations
• Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer
  NCT05508906 · Phase: Phase 1 · Ages: 18 Years and older · Sex: All (male and female) · 16 locations

Common questions

How many trials study Everolimus for Metastatic Breast Cancer?

3 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.